A new drug called fluoromethylcholine blocked TMAO production and reversed kidney disease in mice, improving kidney function by 39% and reducing kidney scarring by 41%, according to a 2026 study in the Journal of the American Society of Nephrology. Gram Research analysis shows this is the first evidence that targeting gut bacteria’s TMAO production can actually reverse established kidney damage, not just prevent it.
According to Gram Research analysis, scientists discovered that a special compound called fluoromethylcholine can stop and even reverse kidney disease in mice. The research shows that kidney damage happens partly because of a substance called TMAO that our gut bacteria make. When researchers blocked TMAO production with this new drug, mice with established kidney disease showed dramatic improvements—their kidney function improved by 39% and scarring in their kidneys decreased by 41%. This finding is exciting because it suggests a completely new way to treat kidney disease that might work even after damage has already started.
Key Statistics
A 2026 study of 50 mice published in the Journal of the American Society of Nephrology found that fluoromethylcholine treatment increased kidney function by 39% and reduced kidney scarring by 41% in mice with established chronic kidney disease.
According to research reviewed by Gram, mice with kidney disease showed 15-fold higher TMAO levels, but fluoromethylcholine treatment virtually eliminated circulating TMAO and reversed multiple kidney dysfunction markers including creatinine and cystatin C levels.
A 2026 animal study demonstrated that blocking gut-microbial TMAO production halted kidney disease progression and promoted 41% reduction in tubulointerstitial fibrosis, suggesting a novel therapeutic approach for established chronic kidney disease.
The Quick Take
- What they studied: Can blocking a gut bacteria product called TMAO actually reverse kidney disease that’s already started, not just prevent it?
- Who participated: 50 laboratory mice were divided into groups. Some had one kidney removed and ate a high-fat diet with extra choline (a nutrient) to create kidney disease. Others had sham surgery as controls.
- Key finding: Mice treated with fluoromethylcholine (FMC), a drug that blocks TMAO production, showed 39% improvement in kidney function and 41% reduction in kidney scarring compared to untreated mice with kidney disease.
- What it means for you: This research suggests a new treatment approach for kidney disease that might work even after damage has developed. However, this is early-stage research in mice—human trials are needed before this becomes a treatment option.
The Research Details
This was a two-phase animal study using mice. In Phase 1, researchers created kidney disease by removing one kidney from some mice and feeding them a high-fat diet with extra choline (which increases TMAO levels). They measured how sick the kidneys became over 12 weeks. In Phase 2, they divided the sick mice into two groups: one continued the same diet, while the other received fluoromethylcholine (FMC), a drug designed to block TMAO production. They tracked kidney health for 8 more weeks.
The researchers measured kidney function using multiple tests including glomerular filtration rate (how well kidneys filter blood), creatinine and cystatin C levels (kidney damage markers), and looked at kidney tissue under microscopes to see scarring and fibrosis (stiffening of tissue). They also measured TMAO levels in the blood and other uremic toxins (waste products that build up in kidney disease).
This approach is powerful because it tests whether blocking TMAO can actually reverse disease that’s already established, not just prevent it from starting. The two-phase design lets researchers first confirm they created kidney disease, then test whether the treatment works.
Most kidney disease research focuses on prevention—stopping disease before it starts. This study is important because it asks a harder question: can we fix kidneys that are already damaged? The two-phase design is scientifically rigorous because it separates the disease-creation phase from the treatment phase, making it clear that improvements come from the drug, not from preventing disease in the first place.
This study was published in the Journal of the American Society of Nephrology, a highly respected kidney research journal. The researchers used multiple measurements of kidney function rather than relying on just one test, which strengthens confidence in the results. They used a control group that didn’t receive the drug, allowing fair comparison. However, this is animal research in mice, so results may not directly translate to humans. The sample size of 50 mice is reasonable for this type of study, though larger human trials would be needed to confirm these findings apply to people.
What the Results Show
After 12 weeks of the high-fat diet with choline supplementation, mice developed significant kidney disease. Their TMAO levels shot up 15-fold compared to controls. Their kidney function declined by 48% (measured by glomerular filtration rate), and they developed 3.5 times more kidney scarring.
When FMC treatment was added for 8 weeks, the results were striking. Mice receiving FMC showed almost complete elimination of TMAO from their blood. More importantly, their kidney function improved by 39%—essentially reversing much of the decline. Kidney scarring actually decreased by 41%, showing that the drug didn’t just stop damage but reversed existing damage.
Untreated mice continued to get worse during Phase 2, with further increases in TMAO and progressive kidney damage. This contrast clearly shows the drug’s effect. The FMC-treated mice also showed improvements in multiple other kidney damage markers including creatinine, cystatin C, and urinary albumin (protein leaking into urine).
Beyond the main kidney function improvements, FMC treatment reduced several uremic toxins (waste products that accumulate in kidney disease), including indoxyl sulfate and phenylacetylglutamine. These toxins are thought to contribute to kidney damage and overall health problems in kidney disease patients. The drug also improved the urinary albumin-to-creatinine ratio, meaning less protein was leaking into the urine—a sign of better kidney health. Gene expression studies showed that profibrotic genes (genes that promote scarring) were downregulated in treated mice, suggesting the drug works at a molecular level to prevent scarring.
Previous research showed that TMAO is linked to kidney disease development and that blocking TMAO production can prevent kidney disease from starting. This study builds on that work by showing that TMAO inhibition can also reverse established disease—a much more clinically relevant finding. Most kidney disease treatments focus on slowing progression, not reversing damage. If these results hold in humans, this would represent a fundamentally new approach to kidney disease treatment.
This research was conducted in mice, not humans. Mice have different physiology than people, and results don’t always translate directly. The study used a specific model of kidney disease (unilateral nephrectomy with high-fat diet), which may not represent all types of human kidney disease. The treatment period was relatively short (8 weeks in mice), so we don’t know about long-term effects. The study didn’t test different doses of FMC or compare it to other kidney disease treatments. Finally, fluoromethylcholine is an experimental drug that hasn’t been tested in humans yet, so safety and effectiveness in people remain unknown.
The Bottom Line
This research is too early-stage to recommend for human use. Fluoromethylcholine is experimental and hasn’t been tested in people. However, the findings suggest that TMAO-lowering strategies may become important kidney disease treatments in the future. Current kidney disease patients should continue following their doctor’s recommendations and may want to discuss TMAO-lowering approaches (like dietary changes) with their nephrologist. High confidence: This research provides strong mechanistic evidence in animal models. Low confidence: Whether this translates to human benefit remains to be determined.
People with chronic kidney disease or at risk for it should find this research interesting, as it suggests a new treatment avenue. Kidney disease researchers and nephrologists should pay attention to these findings. People interested in gut health and its connection to disease should note this example of how gut bacteria affect organ health. However, people should not seek out fluoromethylcholine or similar drugs outside of clinical trials, as they’re not approved for human use.
In mice, improvements appeared within 8 weeks of treatment. If this drug moves to human trials, it would likely take 5-10 years before it could become available as a treatment. Patients shouldn’t expect immediate reversal of kidney damage—the improvements in mice happened gradually over weeks.
Frequently Asked Questions
Can TMAO from gut bacteria actually cause kidney disease?
Research shows TMAO is clinically linked to kidney disease development. A 2026 study found mice with high TMAO levels developed 48% worse kidney function and 3.5 times more kidney scarring, suggesting TMAO plays a significant role in kidney damage progression.
Is there a drug that can reverse kidney disease?
Fluoromethylcholine, an experimental drug that blocks TMAO production, reversed kidney disease in mice by improving function 39% and reducing scarring 41%. However, this drug hasn’t been tested in humans yet and remains experimental.
What foods increase TMAO levels in the body?
Red meat, eggs, and high-fat dairy products contain choline and carnitine, which gut bacteria convert to TMAO. A 2026 study showed mice fed high-fat diets with choline supplementation developed 15-fold higher TMAO levels and severe kidney disease.
How long does it take to reverse kidney damage?
In mice, kidney function improved significantly within 8 weeks of TMAO-blocking treatment. However, human kidney disease is more complex, and realistic timelines for reversal in people remain unknown pending clinical trials.
Can I lower my TMAO levels naturally without drugs?
Dietary changes may help reduce TMAO production. Increasing fiber intake and limiting red meat, eggs, and high-fat dairy can reduce precursors that gut bacteria convert to TMAO, though research on dietary TMAO reduction in kidney disease patients is still developing.
Want to Apply This Research?
- Track kidney function markers monthly (creatinine, eGFR, and cystatin C from blood tests) and urinary albumin-to-creatinine ratio quarterly. Log these alongside diet changes and any TMAO-lowering interventions to identify patterns.
- Users can reduce TMAO production by limiting red meat, eggs, and high-fat dairy products while increasing fiber intake through vegetables and whole grains. Log dietary choices and kidney function markers to see if dietary TMAO reduction correlates with improved kidney health markers.
- Create a dashboard showing kidney function trends over time. Set reminders for regular lab work. Track dietary TMAO sources and correlate with kidney function tests. Share trends with your nephrologist to inform treatment decisions.
This research is preliminary animal-based science. Fluoromethylcholine is an experimental compound that has not been tested in humans and is not approved for any medical use. People with chronic kidney disease should continue following their doctor’s treatment plan and should not attempt to obtain or use experimental drugs outside of clinical trials. This article is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider, particularly a nephrologist, before making changes to kidney disease treatment or diet.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.